NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candid...
Main Authors: | Remy Thomas, Ghaneya Al-Khadairi, Jessica Roelands, Wouter Hendrickx, Said Dermime, Davide Bedognetti, Julie Decock |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00947/full |
Similar Items
-
NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy
by: Alaa Alsalloum, et al.
Published: (2024-09-01) -
Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model
by: Alaa Alsalloum, et al.
Published: (2024-11-01) -
Frequency and clinical association of NY-ESO-1 gene expression in diffuse large B-cell lymphoma
by: Irma Olarte-Carrillo, et al.
Published: (2022-10-01) -
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
by: Wenjie Gong, et al.
Published: (2021-01-01) -
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
by: Indu Ramachandran, et al.
Published: (2019-10-01)